bluebird bio Inc (NAS:BLUE)
$ 0.405 0.0272 (7.2%) Market Cap: 78.75 Mil Enterprise Value: 376.50 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 31/100

bluebird bio Inc at Bank of America Global Healthcare Conference (Virtual) Transcript

Sep 16, 2021 / 01:10PM GMT
Release Date Price: $11.45 (-0.67%)
Jason Gerberry
BofA Global Research - Analyst

Good day, everybody. My name is Jason Gerberry. I'm one of the biotech analysts of Bank of America. It's my pleasure to be introducing our next company presenter at the Bank of America Healthcare Conference. We are joined by bluebird bio. And we've got the future management team of the genetic disease -- what will be the future genetic disease company.

So for those of you not familiar, bluebird bio will be splitting its oncology and genetic disease businesses sometime in the fourth quarter. So when that change occurs, we've got the management team with us. We've got Andrew Obenshain, who is going to be CEO; Richard Colvin, CMO; and Tom Klima will be Chief Commercial Officer. So I guess first off, gentlemen, thanks so much for joining us in advance of this momentous event for the Company.

Andrew Obenshain
bluebird bio, Inc. - President, Severe Genetic Diseases

Thank you.

Questions & Answers

Jason Gerberry
BofA Global Research - Analyst

So I think a

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot